ASCENT: Patient Subgroup Analyses of Sacituzumab Govitecan vs Single-Agent CT in Metastatic TNBC After ≥2 Prior CT Regimens

In subgroup analyses of the phase III ASCENT trial, sacituzumab govitecan maintained benefit and a consistent safety profile vs single-agent chemotherapy among patients aged ≥65 years, among those in the second-line setting with disease TNBC recurrence ≤12 months after (neo)adjuvant therapy, and when compared with individual chemotherapy agents.